Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.60 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.60 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | DHODH | Q02127 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30108269 | 1.00 | MKNK1 (0.60) | MKNK1MKNK2KDM1AHDAC1DHODH | |
| SCHEMBL27995228 | 0.88 | MKNK1 (0.57) | MKNK1MKNK2KDM1AHDAC1DHODH | |
| SCHEMBL13876033 | 0.86 | KDM1A (0.54) | MKNK1MKNK2KDM1AHDAC1DHODH | |
| SCHEMBL31301420 | 0.86 | MKNK1 (0.62) | MKNK1MKNK2KDM1AHDAC1DHODH | |
| SCHEMBL1843427 | 0.86 | MKNK1 (0.62) | MKNK1MKNK2KDM1AHDAC1DHODH | |
| SCHEMBL1758395 | 0.84 | MKNK1 (0.68) | MKNK1MKNK2DHODHCYP11B2MAP4K4 | |
| SCHEMBL30416364 | 0.84 | MKNK1 (0.62) | MKNK1MKNK2CYP11B2MAP4K4CYP11B1 | |
| SCHEMBL30108186 | 0.82 | MKNK1 (0.65) | MKNK1MKNK2CYP11B2MAP4K4CYP11B1 | |
| SCHEMBL28017939 | 0.81 | KDM1A (0.50) | MKNK1MKNK2KDM1AHDAC1DHODH | |
| SCHEMBL6754398 | 0.81 | MKNK1 (0.67) | MKNK1MKNK2CYP11B2MAP4K4CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579367-B2 | Aryl substituted pyridines and the use thereof | PURDUE PHARMA L.P. (US) | 2009-08-25 | — | — | US | claimed |
| US-20080194627-A9 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2008-08-14 | — | — | US | claimed |
| US-20070010554-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-01-11 | — | — | US | claimed |
| EP-1432419-A1 | ARYL SUBSTITUTED PYRIDINECARBOXAMIDES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2004-06-30 | — | — | EP | claimed |
| US-20030055088-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. | 2003-03-20 | — | — | US | claimed |
| WO-2003022276-A1 | ARYL SUBSTITUTED PYRIDINECARBOXAMIDES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2003-03-20 | — | — | WO | claimed |
| CN-101932577-B | Heteroaryl-substituted piperidines | BAYER HEALTHCARE AG | 2013-07-17 | — | — | CN | disclosed |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| WO-2009068214-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-04 | — | — | WO | disclosed |
| US-20080194627-A9 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2008-08-14 | — | — | US | disclosed |
| US-20070010554-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-01-11 | — | — | US | disclosed |
| US-7105549-B2 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2006-09-12 | — | — | US | disclosed |
| EP-1432419-A1 | ARYL SUBSTITUTED PYRIDINECARBOXAMIDES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2004-06-30 | — | — | EP | disclosed |
| US-20030055088-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. | 2003-03-20 | — | — | US | disclosed |
| WO-2003022276-A1 | ARYL SUBSTITUTED PYRIDINECARBOXAMIDES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194627-A9 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1C | MKNK1 4472/4885MKNK2 4569/4885KDM1A 469/4885 |
| US-20030055088-A1 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1D | MKNK1 4334/4885MKNK2 4509/4885KDM1A 445/4885 |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | MKNK1 2957/4885MKNK2 2801/4885KDM1A 3906/4885 |
| US-20070010554-A1 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1C | MKNK1 4472/4885MKNK2 4569/4885KDM1A 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.